参考文献/References:
[1] Sala V,Della Sala A,Hirsch E,et al. Signaling pathways underlying anthracycline cardiotoxicity[J]. Antioxid Redox Signal,2020,32(15):1098-1114.
[2] Liu YP,Wen R,Liu CF,et al. Cellular and molecular biology of sirtuins in cardiovascular disease[J]. Biomed Pharmacother,2023,164:114931.
[3] Vashi R,Patel BM. NRF2 in cardiovascular diseases:a ray of hope![J]. J Cardiovasc Transl Res,2021,14(3):573-586.
[4] Li D,Liu X,Pi W,et al. Fisetin attenuates doxorubicin-induced cardiomyopathy in vivo and in vitro by inhibiting ferroptosis through SIRT1/Nrf2 signaling pathway activation[J]. Front Pharmacol,2021,12:808480.
[5] Lu G,Liu Q,Gao T,et al. Resveratrol and FGF1 synergistically ameliorates doxorubicin-induced cardiotoxicity via activation of SIRT1-NRF2 pathway[J]. Nutrients,2022,14(19):4017.
[6] Ren J,Yang L,Zhu L,et al. Akt2 ablation prolongs life span and improves myocardial contractile function with adaptive cardiac remodeling:role of Sirt1-mediated autophagy regulation[J]. Aging Cell,2017,16(5):976-987.
[7] Li W,Cao J,Wang X,et al. Ferruginol restores SIRT1-PGC-1α-mediated mitochondrial biogenesis and fatty acid oxidation for the treatment of DOX-induced cardiotoxicity[J]. Front Pharmacol,2021,12:773834.
[8] Liu D,Ma Z,Xu L,et al. PGC1α activation by pterostilbene ameliorates acute doxorubicin cardiotoxicity by reducing oxidative stress via enhancing AMPK and SIRT1 cascades[J]. Aging(Albany NY),2019,11(22):10061-10073.
[9] Liang Z,Chen Y,Wang Z,et al. Protective effects and mechanisms of psoralidin against adriamycin-induced cardiotoxicity[J]. J Adv Res,2022,40:249-261.
[10] Upadhyay S,Mantha AK,Dhiman M. Glycyrrhiza glabra(Licorice) root extract attenuates doxorubicin-induced cardiotoxicity via alleviating oxidative stress and stabilising the cardiac health in H9c2 cardiomyocytes[J]. J Ethnopharmacol,2020,258:112690.
[11] Wang Z,Chen Y,Gu M,et al. Protective effects and mechanisms of lycorine against adriamycin-induced cardiotoxicity[J]. Phytomedicine,2022,102:154178.
[12] Herzig S,Shaw RJ. AMPK:guardian of metabolism and mitochondrial homeostasis[J]. Nat Rev Mol Cell Biol,2018,19(2):121-135.
[13] Li X,Wang X,Wang B,et al. Dihydromyricetin protects against doxorubicin-induced cardiotoxicity through activation of AMPK/mTOR pathway[J]. Phytomedicine,2022,99:154027.
[14] Luo XY,Zhong Z,Chong AG,et al. Function and mechanism of trimetazidine in myocardial infarction-induced myocardial energy metabolism disorder through the SIRT1-AMPK pathway[J]. Front Physiol,2021,12:645041.
[15] Wu WY,Cui YK,Hong YX,et al. Doxorubicin cardiomyopathy is ameliorated by acacetin via Sirt1‐mediated activation of AMPK/Nrf2 signal molecules[J]. J Cell Mol Med,2020,24(20):12141-12153.
[16] Wang AJ,Tang Y,Zhang J,et al. Cardiac SIRT1 ameliorates doxorubicin-induced cardiotoxicity by targeting sestrin 2[J]. Redox Biol,2022,52:102310.
[17] Jalgaonkar MP,Parmar UM,Kulkarni YA,et al. SIRT1-FOXOs activity regulates diabetic complications[J]. Pharmacol Res,2022,175:106014.
[18] Li C,Guo Z,Liu F,et al. PCSK6 attenuates cardiac dysfunction in doxorubicin-induced cardiotoxicity by regulating autophagy[J]. Free Radic Biol Med,2023,203:114-128.
[19] Wang YQ,Cao Q,Wang F,et al. SIRT1 protects against oxidative stress-induced endothelial progenitor cells apoptosis by inhibiting FOXO3a via FOXO3a ubiquitination and degradation [J]. J Cell Physiol,2015,230(9):2098-2107.
[20] Liu MH,Shan J,Li J,et al. Resveratrol inhibits doxorubicin-induced cardiotoxicity via sirtuin 1 activation in H9c2 cardiomyocytes[J]. Exp Ther Med,2016,12(2):1113-1118.
[21] Wang F,Chan CH,Chen K,et al. Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation[J]. Oncogene,2012,31(12):1546-1557.
[22] Qi J,Wang F,Yang P,et al. Mitochondrial fission is required for angiotensin Ⅱ-induced cardiomyocyte apoptosis mediated by a Sirt1-p53 signaling pathway[J]. Front Pharmacol,2018,9:176.
[23] Zhang C,Feng Y,Qu S,et al. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53[J]. Cardiovasc Res,2011,90(3):538-545.
[24] Xiao M,Tang Y,Wang J (a) ,et al. A new FGF1 variant protects against adriamycin-induced cardiotoxicity via modulating p53 activity[J]. Redox Biol,2022,49:102219.
[25] Zhang C,Qu S,Wei X,et al. HSP25 down-regulation enhanced p53 acetylation by dissociation of SIRT1 from p53 in doxorubicin-induced H9c2 cell apoptosis[J]. Cell Stress Chaperones,2016,21(2):251-260.
[26] Huang Y,Xu W,Zhou R. NLRP3 inflammasome activation and cell death[J]. Cell Mol Immunol,2021,18(9):2114-2127.
[27] Zheng Y,Xu L,Dong N,et al. NLRP3 inflammasome:the rising star in cardiovascular diseases[J]. Front Cardiovasc Med,2022,9:927061.
[28] Zhai J,Tao L,Zhang S,et al. Calycosin ameliorates doxorubicin-induced cardiotoxicity by suppressing oxidative stress and inflammation via the sirtuin 1-NOD-like receptor protein 3 pathway[J]. Phytother Res,2020,34(3):649-659.
[29] Sun Z,Lu W,Lin N,et al. Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1[J]. Biochem Pharmacol,2020,175:113888.
[30] Reis-Mendes A,Ferreira M,Duarte JA,et al. The role of inflammation and antioxidant defenses in the cardiotoxicity of doxorubicin in elderly CD-1 male mice[J]. Arch Toxicol,2023,97(12):3163-3177.
[31] Basak M,Das K,Mahata T,et al. RGS7 balances acetylation/de-acetylation of p65 to control chemotherapy-dependent cardiac inflammation[J]. Cell Mol Life Sci,2023,80(9):255.
[32] Yuan YP,Ma ZG,Zhang X,et al. CTRP3 protected against doxorubicin-induced cardiac dysfunction,inflammation and cell death via activation of Sirt1[J]. J Mol Cell Cardiol,2018,114:38-47.
[33] Oberdoerffer P,Miller KM. Histone H2A variants:diversifying chromatin to ensure genome integrity[J]. Semin Cell Dev Biol,2023,135:59-72.
[34] Kuno A,Hosoda R,Tsukamoto M,et al. SIRT1 in the cardiomyocyte counteracts doxorubicin-induced cardiotoxicity via regulating histone H2AX[J]. Cardiovasc Res,2023,118(17):3360-3373.